Boston Scientific Corporation (NYSE: BSX) announced the schedule of the Company's major events and news announcements at the 59th Annual Scientific Session of the American College of Cardiology/i2 Summit, March 13-16 in Atlanta. "We look forward to announcing 12-month results from the PERSEUS clinical program, which will provide important data on our third-generation drug-eluting stent, the TAXUS® Element™ Paclitaxel-Eluting Stent," said Keith Dawkins, M.D., Senior Vice President and Chief Medical Officer for Boston Scientific. "The PERSEUS trials are designed to demonstrate that the proven TAXUS drug and polymer combination can be successfully transferred to the innovative Element platform without compromising safety and efficacy. The TAXUS Element Stent's novel architecture and platinum chromium alloy offer physicians significant improvements in flexibility, visibility and deliverability, as well as reduced recoil." Schedule of Events (All times are ET; all events are held at the Georgia World Congress Center.)

Monday, March 15

- PERSEUS 12-Month Results. Dean Kereiakes, M.D., will present 12-month safety and efficacy data on the TAXUS Element Stent from the PERSEUS clinical program, which is studying more than 1,600 patients in two parallel trials at 90 centers worldwide. The pivotal PERSEUS Workhorse trial is evaluating the safety and efficacy of the TAXUS Element Stent compared to Boston Scientific's first-generation TAXUS® Express® Paclitaxel-Eluting Stent in 1,262 patients with de novo lesions. The PERSEUS Small Vessel trial compares the performance of the TAXUS Element Stent in 224 patients with small vessels (greater than or equal to 2.25 to less than 2.75 mm in diameter and less than or equal to 20 mm in length) to a matched historical control group of 125 patients treated with the Express® bare-metal stent. The PERSEUS data will be used to support regulatory approvals in Europe, the U.S. and Japan. Results will be presented from 11:06 to 11:16 a.m. during a late-breaking trial session in the Murphy Ballroom. The Company plans to issue a press release at this time.

- PROMUS® and TAXUS Stents: Multi-Vessel Stenting. Dr. Kereiakes will present results from a pooled analysis of the SPIRIT III and SPIRIT IV clinical trials assessing the performance of the XIENCE V® (PROMUS®) Everolimus-Eluting Stent versus the TAXUS Express Stent in patients undergoing multi-vessel stenting. Results will be presented during a poster session from 1:30 to 4:30 p.m. in Hall B5.

- PROMUS Registry Data. Upendra Kaul, M.D., will present one-year results from the SPIRIT V post-approval registry evaluating the XIENCE V (PROMUS) Stent in real-world practice. Results will be presented during a poster session from 3:30 to 4:30 p.m. in Hall B5.

- HORIZONS AMI Diabetic Analysis. Bernhard Witzenbichler, M.D., will present results from an analysis of the HORIZONS AMI trial on the safety and efficacy of the TAXUS Express Stent in diabetic patients with acute myocardial infarction (AMI) undergoing primary angioplasty. HORIZONS AMI is the largest randomized trial to compare the use of drug-eluting stents to bare-metal stents for the treatment of heart attack patients. Results will be presented during an oral poster session from 4:30 to 4:42 p.m. in Room B315.

Tuesday, March 16

- SYNTAX Data: Stent Thrombosis and Graft Occlusion. Ted Feldman, M.D., will present an analysis of two-year data from the SYNTAX trial assessing the incidence of very late stent thrombosis and graft occlusion in high-risk patients. SYNTAX is the first randomized, controlled clinical trial comparing percutaneous coronary intervention (PCI) using the TAXUS Express Stent to coronary artery bypass graft (CABG) surgery in patients with left main and/or three-vessel disease. Results will be presented during an oral poster session from 8:00 to 8:12 a.m. in Room B315.

- PROMUS and TAXUS Stents: Small Vessels. James Hermiller, Jr., M.D., will present results from a pooled analysis of the SPIRIT III and SPIRIT IV clinical trials assessing the performance of the XIENCE V (PROMUS) Stent versus the TAXUS Express Stent in patients with small vessels. Results will be presented during an oral poster session from 8:24 to 8:36 a.m. in Room B315.

- SYNTAX Data: Renal Insufficiency. David Holmes, M.D., will present an analysis of two-year data from the SYNTAX trial assessing the effect of baseline renal insufficiency on outcomes in patients with left main and/or three-vessel disease who were revascularized with either PCI using a TAXUS Express Stent or CABG. Results will be presented during an oral poster session from 11:18 to 11:30 a.m. in Room B315.

Boston Scientific will present its latest products at booth #414 in the Exhibit Hall, including its drug-eluting stent, cardiac rhythm management, peripheral intervention and imaging technologies.

TAXUS, Express, Element and PROMUS are trademarks of Boston Scientific Corporation or its affiliates. XIENCE V is a trademark of the Abbott Laboratories group of companies. The PROMUS Stent is a private-labeled XIENCE V Stent manufactured by Abbott and distributed by Boston Scientific. The SPIRIT clinical program is sponsored by Abbott.

The safety and efficacy of the TAXUS Express Stent have not been established in patients with left main and/or multi-vessel disease. In the United States, the TAXUS Element Stent and PROMUS Element Stent are investigational devices and are limited by applicable law to investigational use only and are not available for sale.

Source
Boston Scientific